Brief: RenovoRx Q3 Net Income USD -1.421 Million
14/11/2023 13:30
Nov 14 (Reuters) - RenovoRx Q3 basic EPS USD -0.13. * Q3 operating expenses USD 2.983 million * Q3 operating income USD -2.983 million
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies